Novo Nordisk is preparing to file for approval of the oral version of Wegovy in China, signaling a strategic move to broaden obesity treatment options beyond injectable drugs. This development could open the market to patients reluctant to use injections and help Novo Nordisk challenge Eli Lilly’s early lead in China’s rapidly expanding obesity drug market.
The company’s chief executive confirmed that the regulatory submission would occur within months, marking a critical step after a global rollout that has already achieved millions of prescriptions. The oral format’s rising popularity worldwide highlights its transition from development to commercial success, with Novo Nordisk aiming to replicate this momentum in China.
China represents a vital battlefield due to its large patient population and the complexities surrounding intellectual property rights. Although semaglutide’s patent in China expired recently, Novo Nordisk retains regulatory data protection for the product until early next year. In March, the country’s Supreme Court upheld the validity of Novo’s semaglutide patent, supporting the company’s efforts to maintain pricing power and market share in the face of incoming competition.
Meanwhile, Eli Lilly has already taken the lead with an oral obesity drug filing accepted by Chinese regulators earlier this year. Lilly’s significant investment in local manufacturing and supply chain infrastructure underscores the company’s long-term commitment to establishing China as both a key market and production hub.
For Novo Nordisk, the approval of oral Wegovy in China means more than just adding a new product; it’s a strategic effort to extend the reach of GLP-1 therapies, improve patient access, and safeguard its franchise amid intensifying global competition. As the oral category gains traction, the battle in China is shaping into a contest over access, pricing, and production capabilities, defining the future landscape of obesity treatment worldwide.